NCT Number: NCT06395519
Phase: PHASE1
Trial Summary: This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor acti – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): 858 Therapeutics, Inc.
Acronym: ERADIC8
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives